The San Diego-based firm reported a net loss of $589,000, or 1 cent per share, significantly narrower than the 7-cent loss analysts polled by FactSet had anticipated. This quarterly performance triggered a massive rally, with the stock jumping 36% to $25.18 in early trading, partially recovering ground after a 22% retreat over the past year.

Total revenue for the period reached $290.4 million, outpacing the $277 million consensus estimate. The company’s core business showed even stronger underlying momentum when excluding the scheduled conclusion of the Tandem Choice program; on this adjusted basis, worldwide sales climbed 15%. This growth was balanced across geographies, as U.S. sales rose 14% and international revenue increased by 17%.

Growth Outlook and Market Positioning

Looking ahead, management provided a long-term outlook for 2026, projecting full-year sales in the range of $1.065 billion to $1.085 billion. While the midpoint of this guidance falls slightly short of the $1.09 billion currently projected by Wall Street, investors focused on the company's immediate operational gains and its ability to expand its global user base in a competitive diabetes-tech landscape.